Karuna Therapeutics, Inc. (KRTX): Price and Financial Metrics


Karuna Therapeutics, Inc. (KRTX)

Today's Latest Price: $90.12 USD

2.15 (2.44%)

Updated May 28 6:55pm

Add KRTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

KRTX Daily Price Range
KRTX 52-Week Price Range

KRTX Stock Price Chart More Charts


KRTX Price/Volume Stats

Current price $90.12 52-week high $152.00
Prev. close $87.97 52-week low $11.24
Day low $89.00 Volume 246,100
Day high $94.20 Avg. volume 344,466
50-day MA $77.45 Dividend yield N/A
200-day MA $59.58 Market Cap 2.35B

Karuna Therapeutics, Inc. (KRTX) Company Bio


Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.


KRTX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

KRTX Latest Social Stream


Loading social stream, please wait...

View Full KRTX Social Stream

Latest KRTX News From Around the Web

Below are the latest news stories about Karuna Therapeutics Inc that investors may wish to consider to help them evaluate KRTX as an investment opportunity.

Karuna Therapeutics to Present Additional Data from the Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology 2020 Annual Meeting

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, announced today that data from the Phase 2 clinical trial evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia will be presented at the American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting, to be held virtually from May 29 to May 30, 2020. The poster and oral presentation will include new and previously reported efficacy and safety data from the Phase 2 clinical trial.

Yahoo | May 27, 2020

Surging Earnings Estimates Signal Good News for Karuna Therapeutics (KRTX)

Karuna Therapeutics (KRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Zacks Investment Research | May 20, 2020

Karuna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business Update

Karuna Therapeutics, Inc. (Nasdaq: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the pote

Business Wire | May 7, 2020

Karuna Therapeutics Appoints Christopher J. Coughlin to its Board of Directors

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced the appointment of Christopher J. Coughlin to its board of directors. Mr. Coughlin will chair Karuna’s audit committee. “We are thrilled to have Chris join our board,” stated Steve Paul, M.D., chief executiv

Business Wire | April 28, 2020

The Zacks Analyst Blog Highlights: Livongo Health, Karuna Therapeutics, Sprouts Farmers Market, PennyMac Financial Services and Strategic Education

The Zacks Analyst Blog Highlights: Livongo Health, Karuna Therapeutics, Sprouts Farmers Market, PennyMac Financial Services and Strategic Education

Zacks Investment Research | April 27, 2020

Read More 'KRTX' Stories Here

KRTX Price Returns

1-mo 5.81%
3-mo 3.28%
6-mo 25.38%
1-year N/A
3-year N/A
5-year N/A
YTD 19.62%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6821 seconds.